Achievements

• Built the Merck global ophthalmology medical affairs organization following the 2024 Eyebiotech acquisition, assembling a multidisciplinary team that developed and implemented the ophthalmology medical affairs strategy while recruiting experienced retinopathy talent. Within five months, the team delivered the foundational medical affairs plan and the 2028 launch-readiness framework.

• Pioneered an enterprise-wide integrated evidence-planning process that positions compounds to address unmet patient needs, closing data gaps by generating persuasive evidence that is communicated to prescribers, regulators, payers, and guideline committees.

• Supported numerous NDA and SNDA filings; most recently the landmark Belsomra (suvorexant) sNDA incorporating the novel safety and efficacy data from a dedicated trial treating insomnia in vulnerable patients with Alzheimer’s disease.

• Directly managed the pivotal clinical trials establishing Vraylar (cariprazine) treatment for depression indications while supporting its successful NDA filings for schizophrenia and bipolar mania.

• Spearheaded the GSK landmark pediatric and adolescent suicidality data analysis leading FDA to recognize a class-wide antidepressant risk, mandating warning labeling for the entire class.

• Campaigned to raise the standard of care for depression by championing full remission rather than simple treatment response, successfully aligning professional societies and patient advocacy groups behind this new therapeutic benchmark

• Transformed modern emergency room protocols as Research Director for the American Foundation for Suicide Prevention, establishing foundational insights on acute crises and creating the scientific framework for the suicidality assessment scales now used globally.